CCL5 and neoplasm: Previous research showed that pericytes facilitate the resistance to temozolomide by releasing CCL5, which binds to the chemokine receptor CCR5 on tumor cells, triggering the DNA-PKcs/AKT pathway to enhance DNA repair and diminish cell death [187].